{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Leukemia&q=ALL", "query": { "q": "ALL", "condition": "Leukemia" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 5249, "total_pages": 525, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Leukemia&q=ALL&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-07-24T05:44:23.472Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04191187", "title": "Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia", "Acute Lymphoblastic Leukemia", "Biphenotypic Acute Leukemia", "Undifferentiated Leukemia", "Prolymphocytic Leukemia", "Myelodysplastic Syndromes", "Chronic Myelogenous Leukemia", "Myeloproliferative Neoplasm", "Relapsed Large Cell Lymphoma", "Mantle Cell Lymphoma", "Hodgkin Lymphoma", "Burkitt Lymphoma", "Relapsed T-Cell Lymphoma", "Relapsed Chronic Lymphocytic Leukemia", "Relapsed Small Lymphocytic Lymphoma", "Relapsed Marginal B-cell Lymphoma", "Relapsed Follicular Lymphoma", "Lymphoplasmacytic Lymphoma" ], "interventions": [ { "name": "Fludarabine", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Total Body Irradiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2019-12-06", "completion_date": "2024-02-14", "has_results": true, "last_update_posted_date": "2025-12-11", "last_synced_at": "2026-07-24T05:44:23.472Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04191187" }, { "nct_id": "NCT02914977", "title": "Low-Dose Daunorubicin in Relapsed/Refractory Acute Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Lymphocytic Leukemia", "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Daunorubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tara Lin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2016-11", "completion_date": "2021-07-15", "has_results": false, "last_update_posted_date": "2022-01-14", "last_synced_at": "2026-07-24T05:44:23.472Z", "location_count": 1, "location_summary": "Fairway, Kansas", "locations": [ { "city": "Fairway", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02914977" }, { "nct_id": "NCT00771056", "title": "Hydroxychloroquine in Untreated B-CLL Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "B-Cell Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "Hydroxychloroquine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Northwell Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2008-07", "completion_date": "2012-01", "has_results": true, "last_update_posted_date": "2016-08-22", "last_synced_at": "2026-07-24T05:44:23.472Z", "location_count": 1, "location_summary": "New Hyde Park, New York", "locations": [ { "city": "New Hyde Park", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00771056" }, { "nct_id": "NCT05947851", "title": "A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Leukemia, Lymphocytic, Chronic, B-Cell", "Leukemia, Chronic Lymphocytic", "Small-Cell Lymphoma", "Lymphoma, Small Lymphocytic", "CLL", "SLL" ], "interventions": [ { "name": "Nemtabrutinib", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 735, "start_date": "2023-08-08", "completion_date": "2035-07-01", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-07-24T05:44:23.472Z", "location_count": 6, "location_summary": "Springdale, Arkansas • Long Beach, California • Pembroke Pines, Florida + 3 more", "locations": [ { "city": "Springdale", "state": "Arkansas" }, { "city": "Long Beach", "state": "California" }, { "city": "Pembroke Pines", "state": "Florida" }, { "city": "Portland", "state": "Oregon" }, { "city": "Spokane", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT05947851" }, { "nct_id": "NCT07257419", "title": "CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed Pediatric ALL", "Hematopoietic Cell Transplantation", "Hematologic Malignancy" ], "interventions": [ { "name": "Anti-Thymocyte Globulin (Rabbit)", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Thiotepa", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Filgrastim", "type": "DRUG" }, { "name": "CliniMACS System", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 70, "start_date": "2026-08-03", "completion_date": "2035-12", "has_results": false, "last_update_posted_date": "2026-07-17", "last_synced_at": "2026-07-24T05:44:23.472Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT07257419" }, { "nct_id": "NCT01186328", "title": "EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoblastic Leukemia, Acute", "Lymphoblastic Leukemia, Acute, Childhood", "Leukemia, Lymphoblastic, Acute, T Cell", "Leukemia, Lymphoblastic, Acute" ], "interventions": [ { "name": "EZN-3042", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "PEG-asparaginase", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Hydrocortisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Therapeutic Advances in Childhood Leukemia Consortium", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 6, "start_date": "2010-08-24", "completion_date": "2012-01-10", "has_results": true, "last_update_posted_date": "2024-02-01", "last_synced_at": "2026-07-24T05:44:23.472Z", "location_count": 6, "location_summary": "Los Angeles, California • Baltimore, Maryland • Minneapolis, Minnesota + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01186328" }, { "nct_id": "NCT07682792", "title": "Golidocitinib in Patients With Mycosis Fungoides/Sézary Syndrome and T-Cell Large Granular Lymphocytic Leukemia", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Mycosis Fungoides/Sezary Syndrome", "T-cell Large Granular Lymphocytic Leukemia" ], "interventions": [ { "name": "Golidocitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2026-09-30", "completion_date": "2032-09-30", "has_results": false, "last_update_posted_date": "2026-07-06", "last_synced_at": "2026-07-24T05:44:23.472Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT07682792" }, { "nct_id": "NCT00006364", "title": "Homoharringtonine in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Childhood Chronic Myelogenous Leukemia", "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Chronic Phase Chronic Myelogenous Leukemia", "Relapsing Chronic Myelogenous Leukemia" ], "interventions": [ { "name": "omacetaxine mepesuccinate", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 50, "start_date": "1999-11", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-23", "last_synced_at": "2026-07-24T05:44:23.472Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006364" }, { "nct_id": "NCT03481881", "title": "Pharmacokinetics of Drugs Administered to Children", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Pediatric ALL" ], "interventions": [ { "name": "Standard of care drug", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Years", "maximum_age": "20 Years", "sex": "ALL", "summary": "0 Years to 20 Years" }, "enrollment_count": 200, "start_date": "2013-08-14", "completion_date": "2033-08-14", "has_results": false, "last_update_posted_date": "2026-01-07", "last_synced_at": "2026-07-24T05:44:23.472Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03481881" }, { "nct_id": "NCT03048344", "title": "A Phase I, Two-part Study to Determine the Recommended Dose and Evaluate the Safety and Tolerability of a Novel Oral Arsenic Trioxide Formulation (ORH-2014) in Subjects With Advanced Hematological Disorders", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Hematological Disorders" ], "interventions": [ { "name": "ORH-2014", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Orsenix LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2016-12-02", "completion_date": "2019-02-28", "has_results": false, "last_update_posted_date": "2019-03-25", "last_synced_at": "2026-07-24T05:44:23.472Z", "location_count": 4, "location_summary": "New York, New York • Nashville, Tennessee • Houston, Texas", "locations": [ { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03048344" } ] }